Latest news

Orchard Therapeutics today announces the appointment of Mark Rothera as President and Chief Executive Officer.

The US Food and Drug Administration (FDA) granted a Rare Paediatric Disease Designation to OTL-101 for the treatment of adenosine deaminase severe combined immunodeficiency, commonly known as ADA-SCID or “bubble baby” disease. 

Orchard Therapeutics Limited announces on May 30th that it has entered a new clinical manufacturing services agreement with PCT Cell Therapy Services, LLC (“PCT”), a Hitachi Group Company.